Orforglipron
An oral, small-molecule GLP-1 receptor agonist designed to avoid the manufacturing and administration complexity of injectable incretins.
Research status: Positive Phase 3 data; among the first oral GLP-1 candidates to reach late-stage trials.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Related in Weight Loss